|
|
Post by nylefty on Aug 22, 2019 23:26:52 GMT -5
|
|
paul
Researcher
Posts: 134
|
Post by paul on Aug 23, 2019 7:06:23 GMT -5
The question now is what action CMED will take. It's been in their hands over two months. How long does it usually take them to determine a price?
|
|
|
|
Post by mnholdem on Aug 23, 2019 7:25:39 GMT -5
I discussed this issue a few years ago when Sanofi priced Afrezza considerable higher than Al Mann wanted. It was a prelude to the Big 3 simultaneouly raising insulin prices in the US by a substantial amount which has led to congressional inquiries. It was disappointing to some that MannKind did NOT lower the price when they took over commercializing Afrezza.
That having been stated, and regardless of Sanofi's pricing, in my opinion preparing for negotiations of foreign pricing is about the ONLY valid reason for initially keeping Afrezza priced at a premium in the USA during launch in the US and international markets. International drug agencies will use US prices to calculate the target price for a drug distributed in their countries. Years down the road, after adoption in foreign markets, can the US price be lowered.
|
|
|
|
Post by mnkdfann on Aug 23, 2019 7:51:50 GMT -5
That having been stated, and regardless of Sanofi's pricing, in my opinion preparing for negotiations of foreign pricing is about the ONLY valid reason for initially keeping Afrezza priced at a premium in the USA during launch in the US and international markets. International drug agencies will use US prices to calculate the target price for a drug distributed in their countries. Years down the road, after adoption in foreign markets, can the US price be lowered. Is that still mostly the case though? News from earlier this month: globalnews.ca/news/5746469/health-canada-drug-price-regulations/"Under the new rules, Canada will change the list of countries the federal drug price regulator, the Patented Medicine Prices Review Board (PMPRB), compares domestic prices to, dropping the United States and Switzerland where prices are highest." It has been reported widely in the past that Canada has the second highest drug prices and only because Canada included the U.S. in the basket of comparison countries. That would suggest that a lot of (most?) nations had already stopped including the U.S. example before Canada recently decided not to. A recent RAND report studied half a dozen nations, and only Canada (at the time) considered U.S. pricing. France, Netherlands, and Spain, for example, certainly did not. The RAND report is linked to in this article: www.aei.org/publication/a-closer-look-at-international-reference-pricing-for-prescription-drugs/ |
|
|
|
Post by mnholdem on Aug 23, 2019 14:38:37 GMT -5
Good info.
|
|
